Class Action Lawsuit Filed Against Iovance Biotherapeutics for Securities Fraud

A securities fraud class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (IOVA). The legal firm Levi & Korsinsky has reminded investors that they have until July 14, 2025, to participate in the case.

The lawsuit alleges that Iovance Biotherapeutics made false and misleading statements to investors, which resulted in financial harm. Investors who suffered losses from investing in IOVA stock between June 12, 2018, and March 27, 2024, are encouraged to join the class action lawsuit.

The legal complaint states that Iovance Biotherapeutics failed to disclose crucial information to its investors. This includes the fact that its biologics license application for lifileucel to treat melanoma contained inaccuracies and deficiencies that were identified by the Food and Drug Administration (FDA).

Additionally, the lawsuit claims that the company did not disclose that the development and commercialization of lifileucel were not on track as previously stated. Iovance Biotherapeutics allegedly failed to inform investors that it had overstated the likelihood of lifileucel receiving FDA approval and being commercialized in the near future.

Moreover, the lawsuit accuses Iovance Biotherapeutics of making false statements and engaging in deceptive practices to inflate the value of its stock. These actions led investors to purchase IOVA shares at artificially inflated prices, resulting in financial losses when the truth was revealed.

Investors who suffered financial harm due to their investment in Iovance Biotherapeutics are encouraged to participate in the class action lawsuit before the July 14, 2025, deadline. By joining the lawsuit, investors can seek to recover their losses and hold the company accountable for its alleged securities fraud.

Levi & Korsinsky, the legal firm representing the investors in this case, is committed to advocating for the rights of those who have been harmed by securities fraud. The firm has a proven track record of successfully litigating complex securities cases and is dedicated to seeking justice for investors who have been misled by companies like Iovance Biotherapeutics.

In conclusion, the securities fraud class action lawsuit against Iovance Biotherapeutics, Inc. highlights the importance of holding companies accountable for their actions. Investors who have suffered financial losses due to alleged securities fraud have the opportunity to seek compensation through the legal system. By joining the class action lawsuit, investors can work towards recovering their losses and ensuring that companies are transparent and honest in their communications with shareholders. If you are a victim of securities fraud, consider participating in the lawsuit to protect your rights and seek justice.